Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells

Sun Mi Kim(Yonsei University), Byoung Chul Cho(Yonsei University), Flavio Solca(Boehringer Ingelheim (Austria)), Eun Mi Kim(National Institute of Fisheries Science), Ji Su Kim(Yonsei University), Soo-Young Choi(Catholic University of Korea), Joo-Hang Kim(CHA University Bundang Medical Center), Hyun Ki Kim(Yonsei University), Chae‐Ok Yun(Hanyang University)
Cancer Letters
May 5, 2010
10.1016/j.canlet.2010.04.006
Cited by 57

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579